SCHEMBL16183695

SCHEMBL16183695

CC(Nc1nc(-c2cccnc2)nc2ccc(-c3cccc(F)c3F)cc12)c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ CLK1 P49759 1/20 0.52
▸ GBA1 P04062 5/20 0.47
▸ PDE5A O76074 5/20 0.44
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ DYRK1A Q13627 1/20 0.42
▸ KCNA5 P22460 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ CYP1A2 P05177 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ USP1 O94782 1/20 0.41
▸ WDR48 Q8TAF3 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183699 0.94 MEN1 (0.55) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183675 0.89 MEN1 (0.63) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183697 0.88 MEN1 (0.57) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183696 0.88 MEN1 (0.57) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183700 0.88 MEN1 (0.58) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL14475987 0.87 MEN1 (0.55) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183698 0.86 MEN1 (0.58) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183766 0.85 MEN1 (0.49) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL16183673 0.83 MEN1 (0.67) MEN1KMT2ACLK1GBA1PDE5A
SCHEMBL14475170 0.82 CYP1A2 (0.59) MEN1KMT2ACLK1GBA1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MEN1 4814/4885KMT2A 800/4885CLK1 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback